SLLN-15 (30mg/kg, PO, 3 times a week) not only inhibits the growth of TNBC in animal model, but also TNBC cell progression to metastases[1].
Overall, oral SLLN-15 reveals a potent anticancer and anti-metastatic activity in mice bearing TNBC[1].
| Animal Model: | BALB/c mice or SCID mice transplanted with mouse mammary carcinoma 4T1 cells and human breast adenocarcinoma MDA-MB-231 cells (1 X 106 cells/ each mouse)[1] |
| Dosage: | 30mg/kg. |
| Administration: | PO, 3 times a week for 40 days. |
| Result: | Tumor allografts grew at a slower rate compared to control groups.
Significant inhibition of the number of lung metastases as visualized.
|
